Related references
Note: Only part of the references are listed.The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
N. Shinohara et al.
BRITISH JOURNAL OF CANCER (2011)
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2011)
Hypothyroidism in Patients With Renal Cell Carcinoma Blessing or Curse?
Manuela Schmidinger et al.
CANCER (2011)
Toxicities of Targeted Therapy and Their Management in Kidney Cancer
Giuseppe Di Lorenzo et al.
EUROPEAN UROLOGY (2011)
Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics
Heli J. Lehtonen
FAMILIAL CANCER (2011)
Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression
Mariette H. W. Kappers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
L. M. Riesenbeck et al.
WORLD JOURNAL OF UROLOGY (2011)
Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma
Shuichi Sato et al.
ENDOCRINE JOURNAL (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Shrinkage of Thyroid Volume in Sunitinib-Treated Patients with Renal-Cell Carcinoma: A Potential Marker of Irreversible Thyroid Dysfunction?
Aljosja Rogiers et al.
THYROID (2010)
Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
Noriko Makita et al.
THYROID (2010)
Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Theo D. Kim et al.
THYROID (2010)
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Hideaki Miyake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
Martin J. Schlumberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Francesco Torino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Is Hypothyroidism a Clinically Relevant Toxicity of Tyrosine Kinase Inhibitors?
Francesco Torino et al.
THYROID (2009)
The clinical implications of the genetics of renal cell carcinoma
Inger Rosner et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Mathis Grossmann et al.
CLINICAL ENDOCRINOLOGY (2008)
Documentation of Thyroid Function in Clinical Studies With Sunitinib: Why Does It Matter?
David H. Garfield et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) - targeted therapy in metastatic renal cell carcinoma (RCC)
T. K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Treatment outcome for metastatic papillary renal cell carcinoma patients
Ellen A. Rormen et al.
CANCER (2006)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Association between development of hypothyroidism and improved survival in patients with head and neck cancer
Marc Nelson et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2006)
Imatinib induces hypothyroidism in patients receiving levothyroxinc
JWB de Groot et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Share Paper
